Telix’s TLX101-Px MAA Validated in Europe, Enters 210-Day Review
Telix’s marketing authorization application for TLX101-Px has been validated in Europe, triggering a 210-day review for its glioma PET imaging candidate. A positive decision would position TLX101-Px as Europe’s first commercial 18F-FET tracer and pave the way for patient selection in the TLX101-Tx glioblastoma program.
1. European MAA Acceptance
On May 1, 2026, Telix received validation of its marketing authorization application for TLX101-Px (Pixlumi) in Europe, initiating a 210-day active assessment period for its glioma imaging tracer.
2. Addressing Clinical Unmet Need
Europe currently lacks a commercial 18F-FET PET tracer for glioma, and TLX101-Px aims to offer high-quality, standardized imaging to differentiate tumor progression from treatment-related changes in both adults and children.
3. Commercial and Development Outlook
Assuming a favorable review outcome, national marketing authorizations are expected to follow quickly, positioning TLX101-Px as the first available FET-PET product in key European markets and enhancing Telix’s growth prospects.
4. Integration with TLX101-Tx Program
TLX101-Px is also being developed as a patient selection and response assessment tool for TLX101-Tx, the company’s glioblastoma therapy in Phase 3 IPAX-BrIGHT dosing, which holds orphan drug designations in Europe and the U.S.